Black Diamond Therapeutics Inc (NASDAQ: BDTX)’s stock price has plunge by -7.55relation to previous closing price of 3.31. Nevertheless, the company has seen a -10.00% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-10-08 that Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program forward in the clinic.
Is It Worth Investing in Black Diamond Therapeutics Inc (NASDAQ: BDTX) Right Now?
Company’s 36-month beta value is 2.47.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BDTX is 43.06M, and currently, short sellers hold a 16.04% ratio of that floaft. The average trading volume of BDTX on October 24, 2024 was 1.16M shares.
BDTX’s Market Performance
BDTX’s stock has seen a -10.00% decrease for the week, with a -33.19% drop in the past month and a -50.88% fall in the past quarter. The volatility ratio for the week is 7.28%, and the volatility levels for the past 30 days are at 7.65% for Black Diamond Therapeutics Inc The simple moving average for the last 20 days is -15.56% for BDTX stock, with a simple moving average of -37.42% for the last 200 days.
Analysts’ Opinion of BDTX
Many brokerage firms have already submitted their reports for BDTX stocks, with Raymond James repeating the rating for BDTX by listing it as a “Outperform.” The predicted price for BDTX in the upcoming period, according to Raymond James is $20 based on the research report published on July 31, 2024 of the current year 2024.
Stifel gave a rating of “Buy” to BDTX, setting the target price at $10 in the report published on June 30th of the previous year.
BDTX Trading at -36.19% from the 50-Day Moving Average
After a stumble in the market that brought BDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.05% of loss for the given period.
Volatility was left at 7.65%, however, over the last 30 days, the volatility rate increased by 7.28%, as shares sank -27.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.91% lower at present.
During the last 5 trading sessions, BDTX fell by -10.00%, which changed the moving average for the period of 200-days by +8.51% in comparison to the 20-day moving average, which settled at $3.62. In addition, Black Diamond Therapeutics Inc saw 8.90% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDTX starting from Versant Venture Capital VI, L., who sale 221,600 shares at the price of $6.32 back on Aug 28 ’24. After this action, Versant Venture Capital VI, L. now owns 3,726,341 shares of Black Diamond Therapeutics Inc, valued at $1,400,556 using the latest closing price.
David Epstein, the Former Employer of Black Diamond Therapeutics Inc, proposed sale 50,000 shares at $6.20 during a trade that took place back on Jul 31 ’24, which means that David Epstein is holding shares at $310,000 based on the most recent closing price.
Stock Fundamentals for BDTX
Current profitability levels for the company are sitting at:
- -17.83 for the present operating margin
- 0.78 for the gross margin
The net margin for Black Diamond Therapeutics Inc stands at -16.46. The total capital return value is set at -0.66. Equity return is now at value -83.38, with -59.70 for asset returns.
Based on Black Diamond Therapeutics Inc (BDTX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.87. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -127.18.
Currently, EBITDA for the company is -86.02 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 33.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.87.
Conclusion
In a nutshell, Black Diamond Therapeutics Inc (BDTX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
